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S264 Poster Session Isignificant morbidity and mortality. Factors likely include pathogen-
esis of the disease as well as prolonged prior exposure to cytotoxic
chemotherapy and immune suppression. Clinical approaches to im-
prove outcomes should optimize disease control while minimizing
toxicity before and after transplant.302
IMPROVED SURVIVAL FOLLOWING HLA-MATCHED RELATED MARROW
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE APLASTIC
ANEMIA: (A 39-YEAR RETROSPECTIVE ANALYSIS)
Burroughs, L.1,2, Woolfrey, A.1,2, Storer, B.1,3, Deeg, H.J.1,2,
Flowers, M.1,2, Martin, P.1,2, Carpenter, P.1,2, Doney, K.1,2,
Appelbaum, F.1,2, Sanders, J.1,2, Storb, R.1,2 1Fred Hutchinson Cancer
Research Center; 2University ofWashington School of Medicine; 3Univer-
sity of Washington School of Public Health
Allogeneic marrow transplantation offers curative therapy for
pediatric patients with severe aplastic anemia. Over the past 4 de-
cades, significant improvements in the long term outcome of pa-
tients treated with allogeneic marrow grafts have resulted from
progress in the prevention and treatment of graft rejection and
graft-versus-host disease (GVHD). Here we report the outcome
of 149 pediatric patients, ages 2-19 years who received HLA-
matched related marrow grafts for treatment of severe aplastic ane-
mia between 1971 and 2009. Patients were divided into 3 groups,
reflecting changes in conditioning and GVHD prophylaxis regi-
mens that occurred over time. Group 1 consisted of 100 patients
who were conditioned with Cyclophosphamide (CY; 200 mg/kg)
followed by ‘‘long’’ (102 days) Methotrexate (MTX) for GVHD
prevention. Group 2 consisted of 19 patients who received CY fol-
lowed by ‘‘short’’ (days 1, 3, 6, and 11) MTX and cyclosporine
(CSP; through day 180). Group 3 consisted of 30 patients who
were conditioned with CY and horse antithymocyte globulin
(ATG) followed by MTX and CSP for GVHD prevention. The
risk of mortality was significantly different between the 3 groups
(p\0.0001).With a median follow up of 25.2 (range, 0.3-37) years,
the 5-year survival estimates were 66% for group 1, 95% for group
2, and 100% for group 3. There was a suggestion that the risk of re-
jection was different between the 3 groups (p5 0.06) and the 3-year
estimates of graft rejection were 22%, 32%, and 12%, respectively.
The estimated probabilities of grades III-IV acute GVHD were
15% for group 1, 0% for group 2, and 3% for group 3. The
2-year estimates of chronic GVHD were 21%, 21%, and 7%,
respectively. In summary, advances in conditioning and GVHD
prophylaxis regimens as well as supportive care during the past 39
years have led to improved outcomes for pediatric patients with
severe aplastic anemia. These results strongly support the use of
allogeneic marrow transplantation for newly diagnosed pediatric
patients with severe aplastic anemia who have an HLA-matched
related donor.303
HIGH DOSE ORAL BUSULFAN AND INTRAVENOUS MELPHALAN AS
CONDITIONING THERAPY FOR AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANT (HSCT) FOR THE TREATMENT OF PEDIATRIC SOLID
TUMORS
Seber, A.1, Ginani, V.C.1, Gouveia, R.V.1, Zecchin, V.G.1, Barros, D.P.1,
Ibanez, A.1, Marconcini, J.1, Villela, N.1, Felix, O.M.W.O.1,
Simoes, P.C.1, Seixas, M.T.2, Lee, M.L.M.1, Lederman, H.M.1,
Caran, E.M.1, Macedo, C.R.1, Petrilli, A.A.1 1 Instituto de Oncologia+ TBI Focal radiation n (%)
n (%) SMN in field n (% with focal)
Cases with SMN (n56) 5 (83%) 5 (83%)
2/5 (40%)
Controls with SMN (n54) 3 (75%) 2 (50%)
1/2 (50%)Pediatrica - GRAACC - Unifesp, S~ao Paulo, SP, Brazil; 2Universidade
Federal de S~ao Paulo, S~ao Paulo, SP, Brazil
Disseminated or relapsed pediatric solid tumors usually have dis-
mal prognosis and HSCT has been used as a treatment option for
children with chemo-sensitive tumors. With modern intensive pro-
tocols, patients usually have been treated with many different drugs
and may have some degree of renal or cardiac compromise. One in-
teresting alternative would be to use two alkylating agents, busulfan
and melphalan: these drugs are not used in pediatric chemotherapy
protocols, their most important dose-limiting toxicity is marrow
suppression, and they are not toxic to the heart or kidneys. Our ob-
jective is to describe the institutional experience with autologous
HSCTwith busulfan-melphalan for the treatment of relapsed or dis-
seminated pediatric solid tumors.
Results:Nineteen patients with a median age of 11 years (2-33), 10
male, were transplanted, 12/19 with measurable disease. Diagnoses
were alveolar sarcoma (1), desmoplastic small round cell tumor
(DSRCT, 1), Wilms tumor (1), primitive neuroectodermal tumor
(PNET, 2), synovial sarcoma (2), Ewing sarcoma (6, all but 1 with
advanced disease), and stage-4 neuroblastoma (6, only 1 in 1st remis-
sion). All patients had normal marrow aspirate and biopsy prior to
transplant, including immunocytochemistry. Conditioning therapy
was busulfan 1 mg/kg/dose q 6 hours PO for 4 days on D-5 to D-
2 and melphalan 140 mg/m2 IV on D-1. Local irradiation, when
planned, was postponed for the post transplant period. Three re-
ceived bone marrow grafts and 16 peripheral blood stem cells with
target cell dose of 5x106 CD34 cells/kg. All patients engrafted
promptly and none of them had severe toxicities. One had late sinu-
soidal obstruction syndrome and one Ewing sarcoma patient had
Guillain Barre Syndrome at the time of post HSCT irradiation to
his leg. One patient with PNET, the patient with DSRCT, Wilms
tumor and 3/6 with Ewing sarcoma died of their primary disease af-
ter a median of 320 days post HSCT. The patient with alveolar sar-
coma, both with synovial sarcoma, 3 with Ewing sarcoma and all
neuroblastoma patients remain in remission and well after a median
of 10.5 months post transplant (2-119). In conclusion, busulfan-mel-
phalan was very well tolerated and 13/19 patients with advanced tu-
mors remain well and in remission. Longer follow up and a larger
number of patients are needed to define the – promising – role of
this preparative regime for high dose chemotherapy and HSCT in
the treatment of relapsed or disseminated solid tumors.304
INCIDENCE OF SECOND MALIGNANCIES (SMN) IN PEDIATRIC HEMATO-
POIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS: A REPORT COM-
PARING THOSE WITH AND WITHOUT EXOSTOSES
Danner-Koptik, K.1, Kletzel, M.1,2, Dilley, K.J.1,2 1Children’s Memorial
Hospital, Chicago, IL; 2Northwestern University, Chicago, IL
Among 650 patients transplanted in our institution between 1992
and 2008, 19 (3%) are known to have developed a SMNpost-HSCT.
We have studied HSCT survivors who developed exostoses. We
identified 27 patients with clinical and/or radiologic exostoses trans-
planted between 3/1992 and 12/2003. One patient with exostosis had
co-existent malignancies and was treated elsewhere so was excluded
from all analyses due to incomplete data and the possibility of a ge-
netic cancer susceptibility. This group was compared to controls that
were matched for gender, age within 3 years and on same side of pu-
berty, malignancy/not and HSCT type. Our aim is to describe
whether the exostosis patients have a higher risk for developing
SMNs post-HSCT. There were 6/26 (23%) with SMNs in the exos-
tosis group, 4/26 (15%) in the control group (McNemar p-valueAge at first HSCT Time HSCT to SMN A/C GvHD
Mean (range) Mean (range) %
5.5y (0.5-9.1) 11.3y (6.6-16.1) AGvHD 17%
CGvHD 50%
4.9y (1.4-9.1) 9.0y (4.3-13.3) AGvHD 75%
CGvHD 25%
Poster Session I S2650.73). All patients underwent HSCT for malignancies and none who
received a reduced intensity HSCT have developed a SMN to date.
Of those with exostoses, 1 patient had received autologous HSCT
and underwent allogeneic HSCT for myelodysplastic syndrome.
The other SMNs in this group include thyroid papillary carcinoma,
osteogenic sarcoma, GIST, PNET. 3 of 4 SMNs in the control
group had received allogeneic HSCT and all 4 had thyroid papillary
carcinoma. Matched data analysis showed that exostosis cases were
less likely to have been treated with steroids for acute GVHD
(McNemar test p5 0.022) but no differences existed in other clinical
variables examined. However, cases were younger at HSCT (3.9 vs
6.3 yrs, paired t-test p 5 0.004) and had longer F/U than controls
(11.7 vs 8.8 yrs, p 5 0.003). There was no difference in time from
HSCT to SMN (or latest F/U) by Kaplan-Meier (cases5 14.9, con-
trol 5 12.7 yrs, log rank p 5 0.35). Among all 52 patients without
considering exostosis, the age at HSCT was not different for those
with SMN than without (p5 0.87). Descriptive analyses comparing
SMN occurrence in exostosis cases and controls appears in the at-
tached table. In conclusion, for occurrence of exostoses our study
showed only acute GVHD to be different between the groups, and
the likelihood of SMN was similar for cases and controls. Of the
10 SMNs, 50% were thyroid carcinomas, which are common after
low dose radiation exposure to the thyroid.Of note, 43%of the other
solid SMNs among this group occurred in the field of focal radiation
for the primary tumor, highlighting the importance of high dose fo-
cal radiation as a SMN risk.305
REDUCED TOXICITY CONDITIONING (RTC) AND ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) IN 100 CONSECUTIVE PEDIATRIC RECIP-
IENTS: VERY LOW INCIDENCE OF DAY 100 TRANSPLANT RELATED MOR-
TALITY (TRM)
Prakash, S.1, Jin, Z.2, Duffy, D.1, Garvin, J.H.1, Bhatia, M.1,
George, D.1, Bradley, M.B.1, van de Ven, C.1, Morris, E.1,
Harrison, L.1, Baxter-Lowe, L.A.5, Schwartz, J.3, Hawks, R.1,
Foley, S.1, Cairo, M.S.1,3,4 1NewYork-Presbyterian Morgan Stanley
Children’s Hospital, Columbia University, New York, NY; 2NewYork--
Presbyterian Morgan Stanley Children’s Hospital, Columbia University,
New York, NY; 3NewYork-Presbyterian Morgan Stanley Children’s Hos-
pital, Columbia University, New York, NY; 4NewYork-Presbyterian
Morgan Stanley Children’s Hospital, Columbia University, New York,
NY; 5University of California San Francisco, San Francisco, CA
Myeloablative AlloSCT is associated with 20-40% non-relapse
mortality (NRM) in the first 100 days. NRM depends in large part
on graft source, disease and disease status and possibly intensity of
conditioning. RTC may decrease NRM but pediatric data are lim-
ited (Satwani/Cairo BBMT, 2005). We evaluated the feasibility
and toxicity of RTC-AlloSCT in 100 consecutive children (median
age 9.2366.79 yrs) with malignant disease (50) or non-malignant
disease (50) undergoing UCB (n 5 51), MFD (n 5 41), or MUD
(n 5 8) AlloSCT (89 average risk, 11 high risk). Regimens included
Busulfan (6.4-8mg/kg) + Fludarabine (150-180mg/m2) 6 ATG
(8mg/m2) (n 5 45); Cyclophosphamide (60mg/kg) + Fludarabine
(150mg/m2) 6 ATG (8mg/m2) (n 5 20); and Busulfan (12.8-
16mg/kg) + Fludarabine (150mg/m2) + Alemtuzumab (54mg/m2)
(n 5 35). Mean follow-up is 1277 61041 days. Time to neutrophil
and platelet engraftment was 19 610 days and 35 6 26.6 days, re-
spectively. Donor chimerism on day 30, 100 and 365 was 86 627,
92.6 615.8 and 93616, respectively. Cumulative incidence of
aGVHD and cGVHDwas 24.7%64.8% and 18.6%64.7%, respec-
tively. Day 100 and 5 year NRM was 4.1%62.01% and 1563.9 %,
respectively. Overall incidence of primary graft failure (PGF) was
16.5%63.7%. Incidence of PGF with UCB was 33.3%66.8% vs.
0% for MUD and MSD (p \ 0.0001). Incidence of PGF with
UCB in chemo-naive vs. non-chemo-naive patients was 48.3%6
9.3% vs. 10.5%67 % (p\ 0.0072). The 5 year probability of OS
and EFS was 69%65% and 56.4%65.4%, respectively. On univar-
iate analysis, age (p 5 0.12), malignant disease (p 5 0.1), UCB (p 5
0.02), poor risk disease (p 5 0.001), chemo-naive patients (p 5 0.1),
fungal infection (p5 0.01), alemtuzumab based RTC (p5 0.03) and
PGF (p 5 0.03) were associated with poor OS. However, on Cox
proportional hazardmodel basedmultivariate analysis only graft fail-
ure (p5 0.028) and poor risk disease (p5 0.03) were associated withpoor OS. In summary, in this largest reported pediatric series, RTC-
AlloSCTdemonstrated substantially reduced day 100NRMand sus-
tained donor chimerism. However, chemo-naive children undergo-
ing RTC-AlloSCT with UCB grafts have a higher incidence of
PGF, and poor OS.306
DACLIZUMAB AS A SECOND-LINE TREATMENT OF GI GRAFT-VERSUS-
HOST DISEASE IN PEDIATRICS
Hamidieh, A.A.1, Taghizadeh Ghehi, M.2, Hajibabaii, M.2, Jalili, M.1,
Houseini, A.1, Bakhti, O.1, Basirpanah, S.1, Ghavamzadeh, A.1 1Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Steroid-refractory acute gastrointestinal graft-versus-
host disease (GvHD) remains major cause of mortality in pediatric
patients undergoing hematopoietic stem cell transplantation
(HSCT). Among newly developed agents suitable for the treatment
of GvHD, monoclonal antibodies hold much promise.
Methods: we report a series of 10 children who underwent alloge-
neic transplant from June 2007 through June 2009 and were treated
with daclizumab for steroid-refractory acute GI GvHD (grade III-
IV). Median of patients’ age was 6.27 years (range 1-11) and 8 of pa-
tients were male. 8 of 10 patients underwent myeloablative and 2 of
them nonmyeloablative stem cell transplant. Bonemarrow (BM), pe-
ripheral blood (PB), and cord blood were stem cell sources in 4 pa-
tients, 3 patients and one patient respectively. Additionally, double
cord blood in one patient and BM and PB concurrently in another
one were used. Patients were transplanted from full match related
(n5 6), one locus mismatch related (n5 1), two locus mismatch un-
related (n 5 2) and haploidentical related (n 5 1) donor because of
Thalassemia (n5 4), Acute Lymphoblastic Leukemia (n5 2), Aplas-
tic Anemia (n 5 1), Fanconi Anemia (n 5 1), Leukocyte Adhesion
Deficiency (n 5 1), and Wiskott-Aldrich Syndrome (n 5 1). After
first line therapy failed to control GvHD, Daclizumab added at
a dose of 1 mg/kg every 10-14 days until response achieved and/or
maximum 5 doses administered.
Results: 9 of 10 patients (90%) responded to Daclizumab therapy
completely, but one patient failed. There were no infusion-related
reactions. 8 patients developed CMV infection during Daclizumab
therapy. Invasive fungal and bacterial infections occurred in 6 pa-
tients following Daclizumab therapy. Seizure and Guillain-Barre
were important complications after daclizumab therapy in two pa-
tients which may be attributable to this monoclonal antibody. At
a median follow-up of 460 days, 8 patients (80%) are alive and free
of GvHD, severe infections and underlying disease. The remaining
two patients died because of bacterial meningitis and severe non-re-
sponding acute GI GvHD. Limited Chronic GvHD, occurred in 2
patients.
Conclusions:Daclizumab was able to induce complete responses in
pediatric patients with refractory acute gastrointestinal GvHD, but
is associated with morbidity and mortality due to infectious compli-
cations. Aggressive prophylaxis against viral and fungal infections is
recommended.307
A PROSPECTIVE STUDY OF REDUCED INTENSITY CONDITIONING (RIC)
IN CHILDREN UNDERGOING UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) FOR NON-MALIGNANT DISEASES: PRELIMI-
NARY RESULTS DEMONSTRATE A HIGH RATE OF ENGRAFTMENT AND
LOW INCIDENCE OF GVHD
Parikh, S.H., Martin, P.L., Driscoll, T.A., Baker, J., Piersol, K.,
Moffet, J., Stokhuyzen, A., Cash, J., Kurtzberg, J., Szabolcs, P. Duke
University, Durham, NC
Reduced intensity conditioning (RIC) reduces transplant related
morbidity and mortality. However, engraftment remains a challenge
after RIC in children with non-malignant disorders undergoing
UCBT.We designed a novel RIC regimen for such children to study
its efficacy to promote durable engraftment. Outcomes of 8 such
children enrolled between Dec 2008 and July 2010 are presented
in this preliminary analysis. RIC regimen consisted of alemtuzumab
(3.2mg/kg), hydroxyurea (HU), fludarabine (FLU) 150 mg/m2,
